Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) by Quarter
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M) ($M)
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs): $27M in Q2 2026, up 28.6% from a year earlier. That is the highest of the 8 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 27 | +28.6% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 22 | +69.2% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 15 | +87.5% | Form 10-Q (filed 2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 17 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 21 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 13 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 8 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q4 2023 | Dec 31, 2023 | 0 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-daiichisankyo-ar-cur
See every metric in the Merck KPI table. Data updated Oct 26, 2026.